ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARMO
CUSIPN/A
Phone650-779-5075
Debt
Debt-to-Equity RatioN/A
Current Ratio10.82
Quick Ratio10.82
Price-To-Earnings
Trailing P/E Ratio-1.75
Forward P/E Ratio-21.36
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($4.53) per share
Price / Book-11.03
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees31
Outstanding Shares30,410,000
ARMO Biosciences (NASDAQ:ARMO) Frequently Asked Questions
What is ARMO Biosciences' stock symbol?
ARMO Biosciences trades on the NASDAQ under the ticker symbol "ARMO."
How were ARMO Biosciences' earnings last quarter?
ARMO Biosciences Inc (NASDAQ:ARMO) announced its earnings results on Monday, April, 2nd. The company reported ($9.62) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $9.17. View ARMO Biosciences' Earnings History.
What price target have analysts set for ARMO?
4 Wall Street analysts have issued 12 month price targets for ARMO Biosciences' stock. Their predictions range from $50.00 to $75.00. On average, they anticipate ARMO Biosciences' stock price to reach $60.50 in the next twelve months. View Analyst Ratings for ARMO Biosciences.
Are investors shorting ARMO Biosciences?
ARMO Biosciences saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 419,615 shares, a decrease of 67.5% from the April 30th total of 1,291,715 shares. Based on an average trading volume of 959,811 shares, the days-to-cover ratio is currently 0.4 days. Approximately 3.1% of the shares of the stock are short sold. View ARMO Biosciences' Current Options Chain.
Who are some of ARMO Biosciences' key competitors?
Some companies that are related to ARMO Biosciences include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), FibroGen (FGEN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY) and HUTCHISON CHINA/S (HCM).
Who are ARMO Biosciences' key executives?
ARMO Biosciences' management team includes the folowing people:
- Dr. Peter Van Vlasselaer, Founder, Pres, CEO & Director (Age 59)
- Mr. Herbert C. Cross, Chief Financial Officer (Age 46)
- Dr. Joseph Leveque, Chief Medical Officer (Age 57)
- Dr. Martin Oft, Founder and VP of Pre-Clinical & Clinical Devel. (Age 51)
- Dr. Russell T. Kawahata, VP of Technical Operations (Age 64)
When did ARMO Biosciences IPO?
(ARMO) raised $100 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.
When does ARMO Biosciences' lock-up period expire?
ARMO Biosciences' lock-up period expires on Wednesday, July 25th. ARMO Biosciences had issued 7,529,412 shares in its IPO on January 26th. The total size of the offering was $128,000,004 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Has ARMO Biosciences been receiving favorable news coverage?
News coverage about ARMO stock has been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ARMO Biosciences earned a news impact score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 48.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are ARMO Biosciences' major shareholders?
ARMO Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (3.97%), BlackRock Inc. (2.70%), JPMorgan Chase & Co. (1.09%), Redmile Group LLC (0.98%), Wells Fargo & Company MN (0.89%) and Franklin Resources Inc. (0.58%). View Institutional Ownership Trends for ARMO Biosciences.
Which institutional investors are buying ARMO Biosciences stock?
ARMO stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, BlackRock Inc., JPMorgan Chase & Co., Redmile Group LLC, Wells Fargo & Company MN, Franklin Resources Inc., Millennium Management LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for ARMO Biosciences.
How do I buy shares of ARMO Biosciences?
Shares of ARMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ARMO Biosciences' stock price today?
One share of ARMO stock can currently be purchased for approximately $49.98.
How big of a company is ARMO Biosciences?
ARMO Biosciences has a market capitalization of $1.52 billion. The company earns $-42,420,000.00 in net income (profit) each year or ($28.52) on an earnings per share basis. ARMO Biosciences employs 31 workers across the globe.
How can I contact ARMO Biosciences?
ARMO Biosciences' mailing address is 575 Chesapeake Drive, Redwood City CA, 94063. The company can be reached via phone at 650-779-5075 or via email at [email protected]
MarketBeat Community Rating for ARMO Biosciences (ARMO)
MarketBeat's community ratings are surveys of what our community members think about ARMO Biosciences and other stocks. Vote "Outperform" if you believe ARMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
